ROCKs as therapeutic targets in cardiovascular diseases

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 3, 2005, Pages 441-451

  Rikitake, Yoshiyuki ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Contraction; Endothelium; Hypertension; Inflammation; Leukocycte; Remodeling; Rho kinase; Smooth muscle

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; GUANINE NUCLEOTIDE BINDING PROTEIN; H 1152P; HYDROXYFASUDIL; MONOCYTE CHEMOTACTIC PROTEIN 1; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OSTEOPONTIN; OXYGEN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY SPASM; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GENE TARGETING; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IN VIVO STUDY; NONHUMAN; PULMONARY HYPERTENSION; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE CONTRACTION; STABLE ANGINA PECTORIS; STRESS FIBER; VASCULAR DISEASE; VASCULITIS;

CARDIOVASCULAR DISEASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES;

EID: 18844393441     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.3.441     Document Type: Review

References (103)

1. Riento K, Ridley AJ. ROCKs: multifunctional kinases in cell behaviour. Nature Rev. Mol. Cell. Biol. 4, 446-456 (2003).
2. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J. Biol. Chem. 270, 29051-29054 (1995).
3. Amano, M, Ito M, Kimura K et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271, 20246-20249 (1996).
4. Ishizaki T, Maekawa M, Fujisawa K et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15, 1885-1893 (1996).
5. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK-α is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 16, 5313-5327 (1996).
6. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and nonmuscle myosin II. J. Physiol. 522, 177-185 (2000).
7. Nakagawa O, Fujisawa K, Ishizaki T et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189-193 (1996).
8. Matsui T, Amano M, Yamamoto T et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15, 2208-2216 (1996).
9. Ishizaki T, Uehata M, Tamechika I et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 57, 976-983 (2000).
10. Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, Sasaki Y. Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J. Neurochem. 81, 9-16 (2002).
11. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93, 225-232 (2002).
12. Kimura K, Ito M, Amano M et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248 (1996).
13. Inada H, Goto H, Tanabe K et al. Rho-associated kinase phosphorylates desmin, the myogenic intermediate filament protein, at unique amino-terminal sites. Biochem. Biophys. Res. Commun. 253, 21-25 (1998).
14. Katoh K, Kano Y, Amano M et al. Rho-kinase-mediated contraction of isolated stress fibers. J. Cell. Biol. 153, 569-584 (2001).
15. Chen XQ, Tan I, Ng CH, Hall C, Lim L, Leung T. Characterization of RhoA-binding kinase ROK-α implication of the pleckstrin homology domain in ROK-α function using region-specific antibodies. J. Biol. Chem. 277, 12680-12688 (2002).
16. Chevrier V, Piel M, Collomb N et al. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J. Cell. Biol. 157, 807-817 (2002).
17. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity. J. Biol. Chem. 274, 32418-32424 (1999).
18. Feng J, Ito M, Kureishi Y et al. Rho-associated kinase of chicken gizzard smooth muscle. J. Biol. Chem. 274, 3744-3752 (1999).
19. Sebbagh M, Renvoize C, Hamelin J et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nature Cell. Biol. 3, 346-352 (2001).
20. Coleman ML, Sahai EA, Yeo M et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nature Cell. Biol. 3, 339-345 (2001).
21. Amano M, Chihara K, Kimura K et al. Formation of accin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275, 1308-1311 (1997).
22. Turner MS, Fen Fen L, Trauger JW, Stephens J, LoGrasso P. Characterization and purification of truncated human Rho-kinase II expressed in Sf-21 cells. Arch. Biochem. Biophys. 405, 13-20 (2002).
23. Ward Y, Yap SF, Ravichandran V et al. The GTP-binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J. Cell. Biol. 157, 291-302 (2002).
24. Sumi T, Matsumoto K, Nakamura T. Specific activation of LIM-kinase-2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 276, 670-676 (2001).
25. Kawano Y, Fukata Y, Oshiro N et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell. Biol. 147, 1023-1038 (1999).
26. Feng J, Ito M, Ichikawa K et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J. Biol. Chem. 274, 37385-37390 (1999).
27. Velasco G, Armstrong C, Morrice N, Frame S, Cohen P. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett. 527, 101-104 (2002).
28. Matsui T, Maeda M, Doi Y et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell. Biol. 140, 647-657 (1998).
29. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275, 3577-3582 (2000).
30. Maekawa M, Ishizaki T, Boku S et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285, 895-898 (1999).
31. Di Cunto F, Imarisio S, Hirsch E et al. Defective neurogenesis in citron kinase knockout mice by altered cytokinesis and massive apoptosis. Neuron 28, 115-127 (2000).
32. Wei L, Roberts W, Wang L et al. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 128, 2953-2962 (2001).
33. Hart MJ, Jiang X, Kozasa T et al. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Gα13. Science 280, 2112-2114 (1998).
34. Kozasa T, Jiang X, Hart MJ et al. p115 RhoGEF, a GTPase activating protein for Gα12 and Gα13. Science 280, 2109-2111 (1998).
35. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
36. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell. Motil. Cytoskeleton 43, 269-287 (1999).
37. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer. Res. 59, 2004-2010 (1999).
38. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nature Med. 5, 221-225 (1999).
39. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vasc. Pharmacol. 39, 187-199 (2002).
40. Wojciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J. Cell. Sci. 114, 1343-1355 (2001).
41. Farah S, Agazie Y, Ohan N, Ngsee JK, Liu XJ. A Rho-associated protein kinase, ROKα, binds insulin receptor substrate-1 and modulates insulin signaling. J. Biol. Chem. 273, 4740-4746 (1998).
42. Sordella R, Classon M, Hu KQ et al. Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Dev. Cell. 2, 553-565 (2002).
43. O'Cochlain DF, Perez-Terzic C, Reyes S et al. Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy. Hum. Mol. Genet. 13, 2505-2518 (2004).
44. Pan J, Singh US, Takahashi T et al. PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J. Cell. Physiol. 202, 536-553 (2005).
45. Sordella R, Jiang W, Chen GC, Curto M, Settleman J. Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113, 147-158 (2003).
46. Niiro N, Koga Y, Ikebe M. Agonist-induced changes in the phosphorylation of the myosin-binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem. J. 369, 117-128 (2003).
47. Mukai Y, Shimokawa H, Matoba T et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15, 1062-1064 (2001).
48. Seko T, Ito M, Kureishi Y et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92, 411-418 (2003).
49. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38, 1307-1310 (2001).
50. Moriki N, Ito M, Seko T et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 27, 263-270 (2004).
51. Surks HK, Mochizuki N, Kasai Y et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Iα. Science 286, 1583-1587 (1999).
52. Ito K, Hirooka Y, Sakai K et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ. Res. 92, 1337-1343 (2003).
53. Ito K, Hirooka Y, Kishi T et al. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 43, 156-162 (2004).
54. Ito K, Hirooka Y, Sagara Y et al. Inhibition of Rho-kinase in the brainstem augments baroreflex control of heart rate in rats. Hypertension 44, 478-483 (2004)
55. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 326, 310-318 (1992).
56. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 39, 319-327 (2002).
57. Shimokawa H, Seto M, Katsumata N et al. Rho-kinase-mediated pathway induces enhanced myosin light-chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43, 1029-1039 (1999).
58. Kandabashi T, Shimokawa H, Miyata K et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 101, 1319-1323 (2000).
59. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105, 1545-1547 (2002).
60. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischaemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 41, 15-19 (2003).
61. Inokuchi K, Ito A, Fukumoto Y et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J. Cardiovasc. Pharmacol. 44, 275-277 (2004).
62. Utsunomiya T, Satoh S, Ikegaki I et al. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br. J. Pharmacol. 134, 1724-1730 (2001).
63. Shimokawa H, Hiramori K, Iinuma H et al. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J. Cardiovasc. Pharmacol. 40, 751-761 (2002).
64. Vicari R, Chaitman B, Keefe D et al. A randomized double-blind placebo-controlled Phase II study on the efficancy and safety of fasudil in patients with stable angina. American College of Cardiology 53rd Annual Scientific Session. New Orleans, LA, USA (2004).
65. Kataoka C, Egashira K, Inoue S et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39, 245-250 (2002).
66. Ikegaki I, Hattori T, Yamaguchi T et al. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. Eur. J. Pharmacol. 427, 69-75 (2001).
67. Sawada N, Itoh H, Ueyama K et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101, 2030-2033 (2000).
68. Shibata R, Kai H, Seki Y et al. Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 103, 284-289 (2001).
69. Eto Y, Shimokawa H, Hiroki J et al. Gene transfer of dominant-negative Rho-kinase suppresses neointimal formation after balloon injury in pigs. Am. J. Physiol. Heart Circ. Physiol. 278, H1744-H1750 (2000).
70. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J. Biol. Chem. 276, 341-347 (2001).
71. Matsumoto Y, Uwatoku T, Oi K et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler. Thromb. Vasc. Biol. 24, 181-186 (2004).
72. Miyata K, Shimokawa H, Kandabashi T et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler. Thromb. Vasc. Biol. 20, 2351-2358 (2000).
73. Shimokawa H, Morishige K, Miyata K et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc. Res. 51, 169-177 (2001).
74. Morishige K, Shimokawa H, Eto Y et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler. Thromb. Vasc. Biol. 21, 548-554 (2001).
75. Hattori T, Shimokawa H, Higashi M et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ. Res. 94, 46-52 (2004).
76. Funakoshi Y, Ichiki T, Shimokawa H et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38, 100-104 (2001).
77. Takeda K, Ichiki T, Tokunou T et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler. Thromb. Vasc. Biol. 21, 868-873 (2001).
78. Kawamura H, Yokote K, Asaumi S et al. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho-kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24, 276-281 (2004).
79. Ishibashi T, Sakamoto T, Ohkawara H et al. Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 681-687 (2003).
80. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105, 1756-1759 (2002).
81. Mallat Z, Gojova A, Sauzeau V et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93, 884-888 (2003).
82. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 94, 385-393 (2004).
83. Fagan KA, Oka M, Bauer NR et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung. Cell. Mol. Physiol. 287, L656-L664 (2004).
84. Nagaoka T, Fagan KA, Gebb SA et al. Inhaled Rho-kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 171, 494-499 (2005).
85. Fukumoto Y, Hirakawa Y, Abe K et al. Intravenous administration of a rho-kinase inhibitor, fasudil, reduces pulmonary vascular resistance in patients with pulmonary hypertension. The 13th Intnatl Symp. Atheroscler. Kyoto, Japan (2003).
86. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
87. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106, 57-62 (2002).
88. Eto M, Barandier C, Rathgeb L et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res. 89, 583-590 (2001).
89. Ming XF, Viswambharan H, Barandier C et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 22, 8467-8477 (2002).
90. Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 24, 1842-1847 (2004).
91. Chitaley K, Wingard CJ, Clinton Webb R et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nature Med. 7, 119-122 (2001).
92. Bivalacqua TJ, Champion HC, Usta MF et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. Sci. USA 101, 9121-9126 (2004).
93. Sah VP, Minamisawa S, Tam SP et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J. Clin. Invest. 103, 1627-1634 (1999).
94. Higashi M, Shimokawa H, Hattori T et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93, 767-775 (2003).
95. Satoh S, Ueda Y, Koyanagi M et al. Chronic inhibition of Rho-kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J. Mol. Cell Cardiol. 35, 59-70 (2003).
96. Bao W, Hu E, Tao L et al. Inhibition of Rho-kinase protects the heart against ischaemia/reperfusion injury. Cardiovasc. Res. 61, 548-558 (2004).
97. Hattori T, Shimokawa H, Higashi M et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109, 2234-2239 (2004).
98. Yada T, Shimokawa H, Hiramatsu O et al. Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischaemia/reperfusion injury in canine coronary microcirculation in vivo. J. Am. Coll. Cardiol. 45, 599-607 (2005).
99. Hirooka Y, Shimokawa H. Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am. J. Cardiovasc. Drugs 5, 31-39 (2005).
100. Liao JK. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288 (2002).
101. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135 (1998).
102. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 23, 729-736 (2003).
103. Thumkeo D, Keel J, Ishizaki T et al. Targeted disruption of the mouse Rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23, 5043-5055 (2003).